1135 IL28B CC GENOTYPE IS ASSOCIATED WITH HIGHER ON-TREATMENT-RESPONSE RATES IN PTS WITH HCV-3: INTERIM RESULTS OF THE WRITE STUDY

Tx shortened: good efficacy Patients with RVR 55/549 (10.0) 23/554 (4.2) 32/554 (5.8) 34/971 (3.5) Patients with cEVR 4/314 (1.3) 7/1166 (0.6) 0/83 (0.0) 2/189 (1.1) Patients with pEVR 0/74 (0.0) 1/748 (0.1) 0/11 (0.0) 0/48 (0.0) Patients without RVR/EVR 1/120 (0.8) 1/588 (0.2) 0/14 (0.0) 0/29 (0.0) Tx shortened: poor efficacy Patients with RVR 7/549 (1.3) 6/554 (1.1) 0/554 (0.0) 1/971 (0.1) Patients with cEVR 7/314 (2.2) 28/1166 (2.4) 0/83 (0.0) 0/189 (0.0) Patients with pEVR 9/74 (12.2) 123/748 (16.4) 1/11 (9.1) 0/48 (0.0) Patients without RVR/EVR 50/120 (41.7) 333/588 (56.6) 4/14 (28.6) 6/29 (20.7) Body weight 180mg/week 1 ( 1200mg/day 8 (0.4) 186 (9.4) 3 (0.3) 16 (1.7)